3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
86
Kidney Neoplasms
25
Neoplasms
24
Breast Neoplasms
18
Gastrointestinal Stromal Tumors
17
Neoplasm Metastasis
15
Carcinoma, Non-Small-Cell Lung
15
Prostatic Neoplasms
8
Urinary Bladder Neoplasms
7
Brain Neoplasms
7
Pancreatic Neoplasms
6
Lung Neoplasms
6
Colorectal Neoplasms
6
Thyroid Neoplasms
5
Stomach Neoplasms
5
Solid Tumors
5
Small Cell Lung Carcinoma
5
Ovarian Neoplasms
5
Neuroendocrine Tumors
5
Melanoma
5
Glioblastoma
5
Carcinoma
5
Sarcoma
4
Liver Neoplasms
4
Esophageal Neoplasms
4
Clear-cell metastatic renal cell carcinoma
4
Carcinoma, Hepatocellular
4
Astrocytoma
4
Adenoma, Islet Cell
4
Thyroid Cancer, Papillary
3
Interventions
pertuzumab
1
pazopanib
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Risk Assessment
1
Radiotherapy
1
Injections, Subcutaneous
1
Focus Groups
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Patient Preference
×
Sunitinib
×
Clear all
NCT01064310
2017-04-17
PISCES
Novartis
Phase 3
Completed
169 enrolled
16 charts